Clinical Trials Directory

Trials / Completed

CompletedNCT07080190

Early Urine Alkalinization and N-Acetylcysteine Administration in the Management of Hair Dye (Paraphenylene Diamine) Intoxication

Assessment of the Role of Early Urine Alkalinization and N-Acetylcysteine Administration in the Management of Hair Dye (Paraphenylene Diamine) Intoxication

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
120 (actual)
Sponsor
South Valley University · Academic / Other
Sex
All
Age
18 Years – 30 Years
Healthy volunteers
Not accepted

Summary

This study aimed to determine the role of early urine alkalinization and N-acetylcysteine administration for the prevention of renal damage following hair dye intoxication

Detailed description

Paraphenylenediamine (PPD) is an organic compound with the formula C6H4(NH2). It is the derivative of aniline, which is a white substance that turns black on oxidation, called paraphenylaniline, which is soluble in hydrogen peroxide. Intoxication with hair dye (PPD) has become a standard method of intentional self-harm in some parts of Africa and Asia because it is cheap and readily available in the market(5). It can cause contact dermatitis in susceptible individuals. The glutathione (GSH) levels are depleted in PPD poisoning. The antioxidant GSH plays a vital role in the maintenance of cell viability, DNA replication, and the regulation of immune cell functions. N-acetylcysteine (NAC) acts as an antioxidant both directly as a glutathione substitute and indirectly as a precursor for glutathione.

Conditions

Interventions

TypeNameDescription
DRUGEarly N-AcetylcysteinePatients received N-acetyl cysteine early (at admission) in the course of treatment of acute hair dye poisoning.
DRUGLate N-AcetylcysteinePatients received the standard treatment of N-acetyl cysteine after starting organ affection in the course of treatment of acute hair dye poisoning.

Timeline

Start date
2022-07-01
Primary completion
2023-06-30
Completion
2023-06-30
First posted
2025-07-23
Last updated
2025-07-23

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07080190. Inclusion in this directory is not an endorsement.